rachat Intra-Cellular Therapies
((Traduction automatisée par Reuters, veuillez consulter la clausede non-responsabilité https://bit.ly/rtrsauto))
Johnson & Johnson JNJ.N a déclarélundi qu’il achèterait le fabricant de médicamentsIntra-Cellular Therapies ITCI.O pour 14,6 milliards dedollars, renforçant ainsi sa présence sur le marché destraitements des troubles neurologiques.
© 2025 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.
